ERBB2 and breast carcinoma: HER2 overexpression is a major determinant of breast cancer progression, and S1P signaling may contribute to this; S1PR4 stimulates the ERK1/2 pathway in ER-negative HER2-positive MDA-MB-453 breast cancer cells through a HER2-dependent mechanism [210].